Monopar Therapeutics

MNPR Nasdaq SEC CIK 1645469
Follow Monopar Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$6.2M −80.3% vs same quarter last year
EPS, diluted −$0.72 −50% vs same quarter last year
Operating cash flow −$6.2M −156.7% vs same quarter last year
Revenue by quarter
$0
$0
$0
Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income11 fiscal years
  • Revenue
  • Net income
−$20M−$15M−$10M−$5M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$0−$13.7M
FY24$0−$15.6M
FY23-−$8.4M
FY22-−$10.5M
FY21-−$9.1M
FY20-−$6.3M
FY19$0−$4.2M
FY18$0−$3.2M
FY17$0−$16.6M
FY16$0−$1.2M
FY15--